Literature DB >> 24242138

Prognostic significance of microRNA-141 expression and its tumor suppressor function in human pancreatic ductal adenocarcinoma.

Zi-Man Zhu1, Yue-Fang Xu, Qin-Jun Su, Jun-Dong Du, Xiang-Long Tan, Yu-Liang Tu, Jing-Wang Tan, Hua-Bao Jiao.   

Abstract

Increasing evidence shows that dysregulation of microRNAs is correlated with tumor development. This study was performed to determine the expression of miR-141 and investigate its clinical significance in pancreatic ductal adenocarcinoma (PDAC). Taqman quantitative RT-PCR was used to detect miR-141 expressions in 94 PDAC tissues and 16 nontumorous pancreatic tissues. Correlations between miR-141 expression and clinicopathologic features and prognosis of patients were statistically analyzed. The effects of miR-141 expression on growth and apoptosis of PDAC cell line (PANC-1) were determined by MTT, colony formation, and flow cytometry assays. Potential target genes were identified by luciferase reporter and Western blot assays. The expression level of miR-141 in PDAC tissues was significantly lower than that in corresponding nontumorous tissues. Downregulation of miR-141 correlated with poorer pT and pN status, advanced clinical stage, and lymphatic invasion. Also, low miR-141 expression in PDAC tissues was significantly correlated with shorter overall survival, and multivariate analysis showed that miR-141 was an independent prognostic factor for PDAC patients. Further, functional researches suggested that miR-141 inhibits growth and colony formation, and enhances caspase-3-dependent apoptosis in PANC-1 cells by targeting Yes-associated protein-1 (YAP1). Therefore, miR-141 is an independent prognostic factor for PDAC patients, and functions as a tumor suppressor gene by targeting YAP1.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24242138     DOI: 10.1007/s11010-013-1897-y

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  34 in total

Review 1.  An update on molecular research of pancreatic adenocarcinoma.

Authors:  Christian Krautz; Felix Rückert; Hans-Detlev Saeger; Christian Pilarsky; Robert Grützmann
Journal:  Anticancer Agents Med Chem       Date:  2011-06       Impact factor: 2.505

2.  MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma.

Authors:  Yukako Imanaka; Soken Tsuchiya; Fumiaki Sato; Yutaka Shimada; Kazuharu Shimizu; Gozoh Tsujimoto
Journal:  J Hum Genet       Date:  2011-02-03       Impact factor: 3.172

3.  Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.

Authors:  Jason C Gonzales; Louis M Fink; Oscar B Goodman; James T Symanowski; Nicholas J Vogelzang; David C Ward
Journal:  Clin Genitourin Cancer       Date:  2011-07-01       Impact factor: 2.872

4.  The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.

Authors:  Susanna Leskelä; Luis J Leandro-García; Marta Mendiola; Jorge Barriuso; Lucía Inglada-Pérez; Iván Muñoz; Beatriz Martínez-Delgado; Andrés Redondo; Javier de Santiago; Mercedes Robledo; David Hardisson; Cristina Rodríguez-Antona
Journal:  Endocr Relat Cancer       Date:  2010-12-21       Impact factor: 5.678

Review 5.  MicroRNAs: small but potent oncogenes or tumor suppressors.

Authors:  Yong Sun Lee; Anindya Dutta
Journal:  Curr Opin Investig Drugs       Date:  2006-06

6.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

7.  Correlation of expression of phosphorylated and non-phosphorylated Yes-associated protein with clinicopathological parameters in esophageal squamous cell carcinoma in a Korean population.

Authors:  Min-Kyung Yeo; Seok-Hyung Kim; Jin Man Kim; Song-Mei Huang; Mi-Ran Kim; Kyu Sang Song; Kyung-Hee Kim
Journal:  Anticancer Res       Date:  2012-09       Impact factor: 2.480

Review 8.  MicroRNA expression profiling of human-induced pluripotent and embryonic stem cells.

Authors:  Amit Sharma; Joseph C Wu
Journal:  Methods Mol Biol       Date:  2013

Review 9.  Roles of microRNAs and myocardial cell differentiation.

Authors:  Tomohide Takaya; Hitoo Nishi; Takahiro Horie; Koh Ono; Koji Hasegawa
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

10.  miR-21 plays a pivotal role in gastric cancer pathogenesis and progression.

Authors:  Zhiyu Zhang; Zejuan Li; Caiping Gao; Ping Chen; Jianjun Chen; Wenzhong Liu; Shudong Xiao; Hong Lu
Journal:  Lab Invest       Date:  2008-09-15       Impact factor: 5.662

View more
  17 in total

Review 1.  Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application.

Authors:  V Taucher; H Mangge; J Haybaeck
Journal:  Cell Oncol (Dordr)       Date:  2016-04-08       Impact factor: 6.730

Review 2.  MicroRNA in pancreatic cancer.

Authors:  Keiichi Yonemori; Hiroshi Kurahara; Kosei Maemura; Shoji Natsugoe
Journal:  J Hum Genet       Date:  2016-06-02       Impact factor: 3.172

Review 3.  RNA interference-based therapy and its delivery systems.

Authors:  Xiuhui Chen; Lingegowda S Mangala; Cristian Rodriguez-Aguayo; Xianchao Kong; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Cancer Metastasis Rev       Date:  2018-03       Impact factor: 9.264

Review 4.  Emerging role of Hippo pathway in gastric and other gastrointestinal cancers.

Authors:  Wei Kang; Alfred S L Cheng; Jun Yu; Ka Fai To
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 5.  A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy.

Authors:  Masahiro Shibata; Kendall Ham; Mohammad Obaidul Hoque
Journal:  Int J Cancer       Date:  2018-07-24       Impact factor: 7.396

Review 6.  MicroRNAs as biomarkers and prospective therapeutic targets in colon and pancreatic cancers.

Authors:  Ganji Purnachandra Nagaraju; Appiya Santharam Madanraj; Sheik Aliya; Balney Rajitha; Olatunji Boladale Alese; Ekamber Kariali; Afroz Alam; Bassel F El-Rayes
Journal:  Tumour Biol       Date:  2015-11-04

Review 7.  Prognostic value of microRNA expression levels in pancreatic adenocarcinoma: a review of the literature.

Authors:  Patrick Wald; X Shawn Liu; Cory Pettit; Mary Dillhoff; Andrei Manilchuk; Carl Schmidt; Evan Wuthrick; Wei Chen; Terence M Williams
Journal:  Oncotarget       Date:  2017-08-16

8.  Antitumor activity of curcumin is involved in down-regulation of YAP/TAZ expression in pancreatic cancer cells.

Authors:  Xiuxia Zhou; Jingna Su; Shaoyan Feng; Lixia Wang; Xuyuan Yin; Jingzhe Yan; Zhiwei Wang
Journal:  Oncotarget       Date:  2016-11-29

Review 9.  Prognostic Role of the MicroRNA-200 Family in Various Carcinomas: A Systematic Review and Meta-Analysis.

Authors:  Jung Soo Lee; Young-Ho Ahn; Hye Sung Won; Der Sheng Sun; Yeo Hyung Kim; Yoon Ho Ko
Journal:  Biomed Res Int       Date:  2017-02-22       Impact factor: 3.411

10.  Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients.

Authors:  Zhuo Li; Yue-Yun Ma; Juan Wang; Xian-Fei Zeng; Rui Li; Wei Kang; Xiao-Ke Hao
Journal:  Onco Targets Ther       Date:  2015-12-31       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.